Aarti Drugs Ltd (AARTIDRUGS)
🎯 Key Takeaways
- Revenue declined 2.4% QoQ to ₹703 in Q1FY27.
- Market Cap
- ₹3,930
- P/E Ratio
- 20.6
- P/B Ratio
- 2.54
- ROE
- 12.3%
- ROCE
- 12.4%
- Debt/Equity
- 0.37
- Div Yield
- 0.46%
- Promoter
- 54.4%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 653 | 602 | 720 | 703 |
| Operating Profit | 68 | 37 | 78 | 80 |
| OPM % | 10.4% | 6.2% | 10.8% | 11.3% |
| Net Profit | 45 | 41 | 55 | 50 |
| EPS | ₹4.95 | ₹4.44 | ₹6.05 | ₹5.49 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 91 | 91 | 91 | 91 |
| Reserves | 1,278 | 1,186 | 1,458 | 1,377 |
| Borrowings | 612 | 590 | 577 | 573 |
| Total Liabilities | 2,575 | 2,430 | 2,815 | 2,612 |
| Fixed Assets | 922 | 835 | 1,070 | 1,068 |
| Investments | 22 | 20 | 27 | 23 |
| Total Assets | 2,575 | 2,430 | 2,815 | 2,612 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +245 |
| Investing | -165 |
| Financing | -82 |
| Net Cash Flow | -2 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 54.7% | 55.0% | 55.0% | 54.4% |
| FII | 2.7% | 2.1% | 1.6% | 1.5% |
| DII | 9.9% | 10.1% | 10.2% | 10.3% |
| Public | 23.6% | 23.4% | 23.7% | 24.1% |
| # Shareholders | 1,52,252 | 1,48,363 | 1,44,946 | 1,43,476 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.37 L Cr | 36.1 | 18.7% | — | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.2 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.6 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | — | 0.43 |
| CIPLA | 1.09 L Cr | 32.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 97.8 | 20.8% | — | 0.45 |
| MANKIND | 1.03 L Cr | 50.6 | 13.9% | — | 0.38 |
| DRREDDY | 1.03 L Cr | 31.9 | 10.1% | — | 0.17 |
| AUROPHARMA | 95,887 | 26.0 | 12.8% | — | 0.20 |
| LUPIN | 93,367 | 16.5 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🟡 Board Meeting2026-09-30Aarti Drugs announced the resignation of Chairman and CEO Prakash Patil effective September 30, 2026, following his early retirement request, and the …
- Announcement2026-09-29Aarti Drugs Ltd announced that its trading window will close on October 1, 2026, remaining shut for 48 hours after the quarter and half-year financial…
- 🟡 Board Meeting2026-09-26Aarti Drugs announced board changes at its September 26, 2026 AGM: Uday Patil retired as Whole-time Director, Nilesh Patil was appointed as Whole-time…
- 🟡 voting results2026-09-26At the 41st AGM on September 26, 2026, shareholders approved all 16 resolutions with overwhelming majorities, including the appointment of directors, …
- 🟡 Board Meeting2026-09-26Aarti Drugs reported consolidated revenue of Rs. 2,568 crores for FY26, up 7% from Rs. 2,403 crores in FY25, with PAT rising 16% to Rs. 312 crores. EB…
- 🟡 Board Meeting2026-09-26Aarti Drugs held its 41st AGM on September 26, 2026 via video conference with 93 shareholders present. The meeting covered approval of audited financi…
- 🟡 Board Meeting2026-09-02No summary available
- 🔴 annual report2026-09-02No summary available
- 🟡 sustainability report2026-09-02Aarti Drugs Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26 to BSE and NSE on September 2, 2026, as mandated un…
- 🟡 Board Meeting2026-08-27The board approved the Aarti Drugs Limited Performance Stock Option Plan 2026, authorizing up to 800,000 stock options for eligible employees, subject…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when AARTIDRUGS files new disclosures
Track AARTIDRUGS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track AARTIDRUGS — FreeFree account · 2 AI queries/day